November 2020: COVID-19 Vaccines

Navigation

By Jeremy Samuel Faust, MD, MS, MA, FACEP | on December 7, 2020 | 0 Comment

shut by Landon Jones, MD, and Richard M. Cantor, MD, FAAP, FACEP The best questions often stem from the inquisitive learner. As educators, we love, and are always humbled by, those moments when we get to say, “I don’t know.” For some of these questions, you may already know the answers. For others, you may never have thought to ask the question. For all, questions, comments, concerns, and critiques are encouraged. Welcome to the Kids Korner. Antibiotics for Strep Question 1: In children with group A strep pharyngitis, what benefit(s) does antibiotic treatment offer? While a potentially reasonable argument may be made about deferring antibiotic treatment of GAS-positive pharyngitis, is antibiotic treatment beneficial? To begin, an earlier RCT by Nelson evaluated 35 children ages 5–11 years with GAS confirmed by culture and randomized patients to penicillin (PCN) treatment or placebo.1 Follow-up visits occurred at 48 hours. Patients treated with PCN had a significantly shorter duration of fever at follow-up, with 28 percent of placebo patients having persistent fever >48 hours but no treated patients having persistent fever (P=0.031). At 48-hour follow-up, children receiving PCN also had significantly shortened times until improved (P=0.008) and until well (P=0.022). A similar shortened duration of fever at 48 hours was seen in another RCT by Pichichero et al.2 A Cochrane meta-analysis by Spinks et al evaluated 27 trials with 12,835 total cases.3 This included both adults and children and included patients with the diagnosis of sore throat, not specifically GAS. Regarding antibiotics versus placebo, the risk ratio of the incidence of developing the secondary complication of otitis media within 14 days following GAS pharyngitis antibiotic treatment was 0.30 (95 percent CI, 0.15–0.58; 11 studies), suggesting that antibiotic therapy decreased the incidence of the complication of otitis media. Similarly, the risk ratio of the incidence of developing “quinsy”—meaning peritonsillar abscess or retropharyngeal abscess—within two months following GAS antibiotic treatment was 0.15 (95 percent CI, 0.05–0.47; eight studies). Lastly, the risk ratio of the incidence of developing acute rheumatic fever (ARF) within two months was 0.27 (95 percent CI, 0.1–0.50; 14 studies). While ARF is traditionally rare in Western countries (

In this month’s episode of ACEP Nowcast, Dr. Jeremy Faust discusses COVID-19 vaccines being developed, treating strep throat in children, when to send COVID-19 patients home, and other highlights from ACEP Now’s November issue.

Topics: benchmarking coronavirus COVID-19 Strep Throat Vaccination

About the Author

Jeremy Samuel Faust, MD, MS, MA, FACEP

Jeremy Samuel Faust, MD, MS, MA, FACEP, is Medical Editor in Chief of ACEP Now, an instructor at Harvard Medical School and an attending physician in department of emergency medicine at Brigham & Women’s Hospital in Boston. Follow him on twitter @JeremyFaust.

View this author's posts »

Comments are closed.

Wiley

You Might Also Like

Related

November 2025 News from the College

The Resurgence of Measles, Mumps, and Health Equity Challenges

ACEP Member Uses ED, Military Training To Set Standards at FEMA

Current Issue

About the Author

Jeremy Samuel Faust, MD, MS, MA, FACEP

Current Issue